CytomX Therapeutics (CTMX) FCF Margin (2014 - 2026)
CytomX Therapeutics (CTMX) posted FCF Margin of 249.06% for Q1 2026, up 92.96% on a QoQ basis from 3536.05% in Q4 2025, and down 20750.0% year-over-year from N/an in Q1 2025.
CytomX Therapeutics (CTMX) FCF Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 249.06% for Q1 2026.
- Quarterly FCF Margin fell 20750.0% year-over-year to 249.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 225.63% (down 17037.0% YoY) and the FY2025 annual result came in at 99.48%, down 3682.0% from the prior year.
- FCF Margin was 249.06% for Q1 2026 at CytomX Therapeutics, up from 3536.05% in the prior quarter.
- Across five years, FCF Margin topped out at 39.58% in Q1 2023 and bottomed at 3536.05% in Q4 2025.
- A 5-year average of 334.69% and a median of 80.67% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 50472 bps — and 2025, when it slumped 348358 bps.
- CytomX Therapeutics' FCF Margin stood at 7.83% in 2022, then tumbled by 931 bps to 80.67% in 2023, then surged by 35 bps to 52.47% in 2024, then sank by 6639 bps to 3536.05% in 2025, then surged by 93 bps to 249.06% in 2026.
- Business Quant data shows CTMX's FCF Margin at 249.06% in Q1 2026, 3536.05% in Q4 2025, and 258.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -249.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -249.06% |
| Dec 31, 2025 | -3,536.05% |
| Sep 30, 2025 | -258.61% |
| Jun 30, 2025 | -84.57% |
| Mar 31, 2025 | -41.56% |
| Dec 31, 2024 | -52.47% |
| Sep 30, 2024 | -62.06% |
| Jun 30, 2024 | -78.22% |
| Mar 31, 2024 | -63.09% |
| Dec 31, 2023 | -80.67% |
| Sep 30, 2023 | -69.18% |
| Jun 30, 2023 | -103.93% |
| Mar 31, 2023 | 39.58% |
| Dec 31, 2022 | -7.83% |
| Sep 30, 2022 | -307.30% |
| Jun 30, 2022 | -269.58% |
| Mar 31, 2022 | -465.14% |
| Dec 31, 2021 | -282.40% |
| Sep 30, 2021 | -326.13% |
| Jun 30, 2021 | -321.92% |